AYA Shares Artrya Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
AI cardiac-imaging software company with rapid adoption potential across clinical screening workflows.
Future value: $6.24 (+153.76%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Exceptional recent momentum, but early-stage execution risk remains high.
- ▾Below 50-day MA (-32.72%)
- ▾Near 52-week low (10.3% of range)
- ▸~154% upside to price target
Is AYA a buy right now?
Trend: AYA is trading below the 50-day average (-30.19%), RSI 47 — neutral momentum, with a 3-month return of -37.00%.
Valuation & quality: Artrya Limited trades on forward P/E -29.8, price-to-book 5.25; fundamentals show net margin 0.0%, return on equity -50.6%, revenue growth -6.7% year on year.
Analyst consensus: 5 analysts have a mean 12-month price target of A$5.50 (+118.4% vs the last close; range A$4.25 – A$7.00), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — AI cardiac-imaging software company with rapid adoption potential across clinical screening workflows.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -2.60% | +19.90% | +24.70% | +23.20% | -33.90% | +5.20% | -16.00% | -29.20% |
Fundamentals
Analyst price target
Technical signals
About Artrya Limited
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Artificial Intelligence picks
Browse: all ASX stocks · Artificial Intelligence picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.